Aside from reducing hyperglycemia and increasing insulin sensitivity, several other beneficial clinical effects have been reported for SGLT-2 inhibitors, including reduced risks of cardiovascular and renal diseases, improved blood pressure control, body weight reduction, and reductions in liver fat content (34–37). This evidence concerns the gene SLC5A2 and kidney disorder.